Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $22.50.
Several equities research analysts recently issued reports on DCTH shares. Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. BTIG Research lowered their price objective on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Zacks Research downgraded Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Evercore set a $27.00 price objective on Delcath Systems in a research note on Thursday, February 26th. Finally, Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th.
Get Our Latest Stock Report on Delcath Systems
Delcath Systems Stock Performance
Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.07. The business had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Sell-side analysts predict that Delcath Systems will post -0.88 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of DCTH. Millennium Management LLC boosted its stake in Delcath Systems by 34.1% during the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock valued at $5,373,000 after buying an additional 107,391 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Delcath Systems by 58.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock worth $1,572,000 after purchasing an additional 45,695 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Delcath Systems by 229.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock valued at $2,288,000 after acquiring an additional 117,118 shares during the last quarter. Legal & General Group Plc acquired a new stake in Delcath Systems in the 2nd quarter valued at approximately $46,000. Finally, Rhumbline Advisers acquired a new stake in Delcath Systems in the 2nd quarter valued at approximately $586,000. Institutional investors own 61.12% of the company’s stock.
About Delcath Systems
Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.
Read More
- Five stocks we like better than Delcath Systems
- Could a Tesla-SpaceX Merger Be Closer Than Investors Think?
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
